AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi
(Bloomberg) -- AstraZeneca Plc agreed to sell U.S. rights to the respiratory medicine Synagis to Sweden's Sobi for at least $1.5 billion, another move in the U.K. drugmaker's efforts to purge its portfolio of aging products.
Sobi, officially Swedish Orphan Biovitrum AB, also gained the right to share the U.S. profits and losses on a potential new medicine, which Astra is developing with Sanofi, that targets the same lung virus Synagis treats, the Cambridge, England-based company said in a statement.
Chief Executive Officer Pascal Soriot has been paring back Astra's portfolio, selling the rights to fading blockbusters such as Nexium for reflux as a new crop emerges, led by Imfinzi and other cancer drugs. The goal is to become “very focused, very lean,” with a shelf full of innovative products that will keep patent exclusivity for years, Soriot said last week.
“The agreement represents good value for AstraZeneca given the size of the upfront payment,” and it allows the drug giant to focus on its core portfolio while keeping a stake in Synagis, Adam Barker, an analyst with Shore Capital Group, said in a note to clients. Synagis is projected to sell $1.3 billion cumulatively from 2019 through 2023, he said.
Sobi shares rose as much as 7.9 percent in Stockholm trading Tuesday, the most since July, while Astra was up as much as 1 percent in London.
Astra gets $1 billion in cash, which it said it plans to use for general corporate purposes, and $500 million worth of Sobi shares. About 130 Astra employee will move to Sobi as part of the transaction.
The U.K. drugmaker is also eligible for as much as $470 million in payments related to Synagis sales and a further $345 million related to development of the experimental drug. Called MEDI8897, it's a monoclonal antibody for prevention of respiratory syncytial virus, the most prevalent cause of pneumonia and other lung infections in infants and young children.
The deal is expected to complete at the start of 2019.
--With assistance from Joe Easton.
To contact the reporter on this story: Marthe Fourcade in Paris at mfourcade@bloomberg.net
To contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, John Lauerman
©2018 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.